

# Prostate Cancer

## Current Awareness Bulletin

August 2021

This Current Awareness Bulletin is produced by the Yeovil Academy Library to provide staff with a range of prostate cancer-related resources to support practice. It includes recently published guidelines and research articles.



In order to get the most from this bulletin, you will need an OpenAthens username and password. This will grant full text access to many of the listed resources. To register for an OpenAthens account go to: [openathens.nice.org.uk](https://openathens.nice.org.uk).

## Systematic Reviews



### [Degarelix for treating advanced hormone-sensitive prostate cancer](#)

Friedemann Zengerling, Joachim J Jakob, Stefanie Schmidt, Joerg J Meerpohl, Anette Blümle, Christine Schmucker, Benjamin Mayer, Frank Kunath

Intervention

Review

5 August 2021

Degarelix is a gonadotropin-releasing hormone antagonist that leads to medical castration used to treat men with advanced or metastatic prostate cancer, or both. It is unclear how its effects compare to standard androgen suppression therapy.

### [Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer](#)

Joel E Rosenberg, Jae Hung Jung, Hunju Lee, Solam Lee, Caitlin J Bakker, Philipp Dahm

Intervention

Review

8 August 2021

Delayed recovery of urinary continence is a major adverse effect of robotic-assisted laparoscopic prostatectomy (RALP) in men undergoing prostate cancer treatment.

[\*\*Olaparib \(Lynparza\) for metastatic castration-resistant prostate cancer \(mCRPC\)\*\*](#)

Systematic Reviews

2021 [Austrian Institute of Health Technology Assessment](#)

[\*\*Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer \(mCRPC\) previously treated with a docetaxel containing regimen\*\*](#)

Systematic Reviews

2021 [Austrian Institute of Health Technology Assessment](#)

[\*\*Enzalutamide \(Xtandi\) for the treatment of adult men with metastatic hormone-sensitive prostate cancer \(mHSPC\) in combination with androgen deprivation therapy \(ADT\)\*\*](#)

Systematic Reviews

2021 [Austrian Institute of Health Technology Assessment](#)

[\*\*MRI-US fusion targeted biopsy for diagnosis of prostate cancer\*\*](#)

Systematic Reviews

2021 [Appropriate Care Guides, Agency for Care Effectiveness \(Singapore\)](#)

[\*\*Treatment Sequences of Androgen Receptor Targeted Agents for Patients with Prostate Cancer\*\*](#)

Systematic Reviews

2021 [CADTH - Health Technology Review](#)

[\*\*Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer\*\*](#)

Systematic Reviews

2021 [CADTH - Health Technology Review](#)

## UpToDate

UpToDate<sup>®</sup> is accessible via the links section of the library intranet [YCloud](#) page or via the [library blog](#). It can also be accessed at [uptodate.com/login](#) with an OpenAthens username and password. To register for an OpenAthens account [click here](#).

[\*\*Screening for prostate cancer\*\*](#)

Literature review current through: Jul 2021. | This topic last updated: Jul 01, 2021.

Prostate cancer is common and is among the main causes of cancer-related death. At the same time, in many cases, prostate cancer grows so slowly that it does not impact survival; hence, routine screening is controversial.

### [Clinical presentation and diagnosis of prostate cancer](#)

Literature review current through: Jul 2021. | This topic last updated: May 19, 2020.

Prostate cancer is among the most common cancers in men worldwide, with an estimated 1,600,000 cases and 366,000 deaths annually. In the United States, 11 percent of men are diagnosed with prostate cancer over their lifetime, with the incidence generally rising with age; there are an estimated 165,000 cases and 29,000 deaths annually. The overall five-year survival rate is over 98 percent.

### [Risk factors for prostate cancer](#)

Literature review current through: Jul 2021. | This topic last updated: Jan 22, 2021.

Prostate cancer is the second most common cancer in men worldwide, with over 1.2 million cases and 358,000 deaths annually, according to data from the World Health Organization (WHO) [GLOBOCAN](#) database. The current lifetime risk of prostate cancer for men living in the United States is estimated to be approximately one in nine [1], but incidence is highly dependent on the number of prostate-specific antigen (PSA)-driven biopsies.

## Journal Articles

If you would like help obtaining any of the articles, please contact the Library.

### NICE Healthcare Databases

---

#### [1. The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer: a survey of UK practice.](#)

**Author(s)** Kinnaird ; Mehta, Ami; Guo, Carina; Payne, Heather; Jenkins, Valerie [et al.](#)

**Source** Acupuncture in Medicine; Aug 2021; vol. 39 (no. 4); p. 394-395

**Language** English

**Publication Date** Aug 2021

**DOI** [10.1177/0964528420959078](#)

**ISSN** 09645284

**Database** CINAHL

[Available in full text at Acupuncture in Medicine from Unpaywall](#)

#### [2. Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK uro-oncologists.](#)

**Author(s)** Bahl ; Challapalli, Amarnath; Jain, Suneil; Payne, Heather

**Source** International Journal of Clinical Practice; Aug 2021; vol. 75 (no. 8); p. 1-5

**Language** English

**Publication Date** Aug 2021

**DOI** [10.1111/ijcp.14338](#)

**ISSN** 13685031

**Database** CINAHL

[Available in full text at International Journal of Clinical Practice from Wiley Online Library Medicine and Nursing Collection 2020](#)

[3. Developing UK Guidance on How Long Men Should Abstain from Receiving Anal Sex before, During and after Interventions for Prostate Cancer.](#)

**Author(s)** Ralph, S

**Source** Clinical oncology (Royal College of Radiologists (Great Britain)); Aug 2021

**Publication Date** Aug 2021

**DOI** [10.1016/j.clon.2021.07.010](https://doi.org/10.1016/j.clon.2021.07.010)

**ISSN** 1433-2981

**Database** Medline

[Available in full text at Clinical oncology \(Royal College of Radiologists \(Great Britain\)\) from Unpaywall](#)

[4. COVID-19: diary of a cancer nurse specialist: Prostate Cancer UK specialist nurse John Robertson describes a typical day during the pandemic.](#)

**Author(s)** Robertson

**Source** Cancer Nursing Practice; Jun 2021 ; p. 17-19

**Language** English

**Publication Date** Jun 2021

**DOI** [10.7748/cnp.20.4.17.s9](https://doi.org/10.7748/cnp.20.4.17.s9)

**ISSN** 14754266

**Database** CINAHL

Since the start of the COVID-19 pandemic in the UK, cancer services have had to adapt and change to accommodate the challenges.

[5. Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre.](#)

**Author(s)** Kum, Francesca; Beckmann, Kerri; Aya, Haleema; Singh, Sohail; Sandhu, Preeti [et al.](#)

**Source** Prostate cancer and prostatic diseases; Jun 2021; vol. 24 (no. 2); p. 549-557

**Publication Date** Jun 2021

**DOI** [10.1038/s41391-020-00313-0](https://doi.org/10.1038/s41391-020-00313-0)

**ISSN** 1476-5608

**Database** Medline

African/Afro-Caribbean men on AS for PCa in the UK are less likely to adhere to scheduled appointments, suggesting a more tailored service addressing their specific needs may be required. While African/Afro-Caribbean men were no more likely to convert to treatment than Caucasian/other men, findings of a potentially higher risk of disease progression signal the need for careful selection and monitoring of African/Afro-Caribbean men on AS.

[6. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.](#)

**Author(s)** Watts, Eleanor L; Fensom, Georgina K; Smith Byrne, Karl; Perez-Cornago, Aurora; Allen, Naomi E [et al.](#)

**Source** International journal of cancer; May 2021; vol. 148 (no. 9); p. 2274-2288

**Publication Date** May 2021

**DOI** [10.1002/ijc.33416](#)

**ISSN** 1097-0215

**Database** Medline

Insulin-like growth factor-I (IGF-I) and testosterone have been implicated in prostate cancer aetiology. Using data from a large prospective full-cohort with standardised assays and repeat blood measurements, and genetic data from an international consortium, we investigated the associations of circulating IGF-I, sex hormone-binding globulin (SHBG), and total and calculated free testosterone concentrations with prostate cancer incidence and mortality.

[Available in full text at International journal of cancer from Wiley Online Library](#)

[Available in full text at International journal of cancer from Unpaywall](#)

[7. Management of newly diagnosed metastatic hormone-sensitive prostate cancer: A survey of UK Uro-oncologists.](#)

**Author(s)** Bahl ; Crabb, Simon; Ford, Dan; Jones, Rob; Malik, Zaf [et al.](#)

**Source** International Journal of Clinical Practice; Apr 2021; vol. 75 (no. 4); p. 1-9

**Language** English

**Publication Date** Apr 2021

**DOI** [10.1111/ijcp.13874](#)

**ISSN** 13685031

**Database** CINAHL

[Available in full text at International Journal of Clinical Practice from Wiley Online Library Medicine and Nursing Collection 2020](#)

[8. Editorial comment on "Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort".](#)

**Author(s)** Mehralivand

**Source** European Radiology; Mar 2021; vol. 31 (no. 3); p. 1642-1643

**Language** English

**Publication Date** Mar 2021

**DOI** [10.1007/s00330-020-07589-9](#)

**ISSN** 09387994

**Database** CINAHL

[Available in full text at European radiology from Unpaywall](#)

[9. Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort.](#)

**Author(s)** Giganti ; Stabile, Armando; Stavrinides, Vasilis; Osinibi, Elizabeth; Retter, Adam [et al.](#)

**Source** European Radiology; Mar 2021; vol. 31 (no. 3); p. 1644-1655

**Language** English

**Publication Date** Mar 2021

**DOI** [10.1007/s00330-020-07256-z](#)

**ISSN** 09387994

**Database** CINAHL

[Available in full text at European radiology from Unpaywall](#)

[10. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.](#)

**Author(s)** Clift ; Coupland, Carol AC; Hippisley-Cox, Julia

**Source** British Journal of General Practice; Feb 2021; vol. 71 (no. 703)

**Language** English

**Publication Date** Feb 2021

**DOI** [10.3399/bjgp20X713957](#)

**ISSN** 09601643

**Database** CINAHL

A substantial number of men in England opt in to opportunistic prostate cancer screening, despite uncertainty regarding its efficacy and harms. The rate of opportunistic prostate cancer screening in the population is likely to have contaminated the CAP trial, making it difficult to interpret the results.

[Available in full text at The British journal of general practice : the journal of the Royal College of General Practitioners from Unpaywall](#)

[11. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank.](#)

**Author(s)** Monroy-Iglesias, Maria J; Russell, Beth; Crawley, Danielle; Allen, Naomi E; Travis, Ruth C [et al.](#)

**Source** International journal of cancer; Feb 2021; vol. 148 (no. 4); p. 825-834

**Publication Date** Feb 2021

**DOI** [10.1002/ijc.33255](#)

**ISSN** 1097-0215

**Database** Medline

We investigated the association between metabolic syndrome (MetS) and its components and risk of prostate cancer (PCa) in a cohort of men enrolled in the UK Biobank. Our study cohort included 220 622 PCa-free men with baseline measurements of triglycerides (TGs), HDL-cholesterol (HDL), glycated hemoglobin (HbA1c), blood pressure (BP), and waist circumference (WC). Multivariable Cox proportional hazards regression was used to analyze associations with PCa for: individual metabolic components (TG, HDL, HbA1c, BP, WC), combinations of two and three components, and MetS overall (three or more components).

[Available in full text at International journal of cancer from Wiley Online Library](#)

[12. Overall survival of black and white men with metastatic castration-resistant prostate cancer \(mCRPC\): a 20-year retrospective analysis in the largest healthcare trust in England.](#)

**Author(s)** Ng, Kenrick; Wilson, Peter; Mutsvangwa, Katherine; Hounsoume, Luke; Shamash, Jonathan

**Source** Prostate cancer and prostatic diseases; Jan 2021

**Publication Date** Jan 2021

**DOI** [10.1038/s41391-020-00316-x](https://doi.org/10.1038/s41391-020-00316-x)

**ISSN** 1476-5608

**Database** Medline

Black men may do better than white men with mCRPC, in the context of equal access to healthcare. The study also suggests a greater margin of benefit of hormone-based therapy in the black subpopulation.

[13. A cross-section of UK prostate cancer diagnostics during the coronavirus disease 2019 \(COVID-19\) era - a shifting paradigm?](#)

**Author(s)** Stroman, Luke; Cathcart, Paul; Lamb, Alastair; Challacombe, Ben; Popert, Rick

**Source** BJU international; Jan 2021; vol. 127 (no. 1); p. 30-34

**Publication Date** Jan 2021

**DOI** [10.1111/bju.15259](https://doi.org/10.1111/bju.15259)

**ISSN** 1464-410X

**Database** Medline

[Available in full text at BJU international from Wiley Online Library](#)

## In the News



[Leading urology nurse selected by charity to become 'clinical champion'](#)

10 June, 2021

The president of the British Association of Urological Nurses (BAUN) is embarking on a project to develop a nurse-led prostate biopsy service in her local area with the support of a cancer charity. Clare Waymont has been selected for Prostate Cancer UK's new clinical champions programme.

[Nurse 'proud to be first in world' to insert prostate implant](#)

25 February, 2021

A nurse in Middlesbrough is believed to have become the first in the world to be trained to insert a revolutionary implant, which helps to reduce the side effects of radiotherapy in prostate cancer patients by up to 70%.

---

This current awareness bulletin contains an inexhaustive selection of information that has not been critically appraised by library staff. It is therefore the responsibility of the reader to appraise this information for accuracy and relevance.

For further information or support please contact Yeovil Academy Library, Level 4, Yeovil District Hospital, Higher Kingston, Yeovil, BA21 4AT; tel 01935 38(4495) or 01935 38(4697), [library@ydh.nhs.uk](mailto:library@ydh.nhs.uk) or visit the library blog at [yeovilacademylibrary.com](http://yeovilacademylibrary.com)

